Ongoing studies involving the drug repositioning approach have identified FDA-approved compounds that enable us to recapitulate MKK3 depletion-dependent effects in different CRC lines both in vitro and xenograft models in nude mice, thus identifying novel promising drugs to potentially translate from bench to bedside. This evidence concerns the gene MAP2K3 and colorectal carcinoma.